Company

Bank

Analyst

Coverage

Opinion

Wk chg

2/14 cls

Depomed Inc. (NASDAQ:DEPO)

Roth Capital Partners

Scott Henry

Downgrade

Neutral (from buy)

1%

$12.30

Henry downgraded on the belief that the share price has caught up to fundamentals after doubling in the past 12 months. He raised his target to $12.50 from $12 after increasing his sales forecasts for migraine drug Cambia diclofenac oral solution to $27M in 2014 and $37M in 2015. Last December, Depomed gained U.S. rights to Cambia from Nautilus Neurosciences Inc.

Genetic Technologies Ltd. (ASX:GTG; NASDAQ:GENE)

Ladenburg Thalmann

Kevin DeGeeter

Upgrade

Buy (from neutral)

31%

$1.90

DeGeeter also introduced a $2.50 target ahead of the anticipated 3Q14 launch in the U.S. of a second-generation BREVAGen genetic test with broader ethnic coverage. The breast cancer stratification test is marketed in the U.S. for use in Caucasian women ages 35 and older. Genetic Technologies expects to validate BREVAGen for use in other ethnic populations this half, and subsequently launch the expanded test in the U.S. DeGeeter also believes the company's recent steps to simplify its operating structure will result in "modest but meaningful reduction in cash burn."